- Push-out Score determined
- After about three and a half years in the position
- Accolades, praise and thanks for Fouse
- Brian Goff taking over
- Fouse will remain as chair of the board at Agios
- Fouse spoke at length and said 159 words
(exechange) — Cambridge, Massachusetts, July 12, 2022 — Jackie Fouse, chief executive of Agios, leaves her position. As announced by Agios Pharmaceuticals Inc. in a news release and in a regulatory filing published on Tuesday, July 12, 2022, Jacqualyn A. (Jackie) Fouse leaves her post as chief executive officer at the biopharmaceutical company, after about three and a half years in the role, effective August 8, 2022.
Jackie Fouse’s duties as CEO will be taken over by Brian Goff, most recently Executive Vice President, Chief Commercial and Global Operations Officer at Alexion Pharmaceuticals, Inc.
The fact that Jackie Fouse’s successor is brought in from outside suggests that the board may seek to stimulate change with fresh ideas and new initiatives.
“Deepen our ability to deliver for patients and shareholders”
Agios did not give an explicit reason for Jackie Fouse’s departure from the CEO post. David Schenkein, chairman, said: “At every step of Agios’ journey, our board and leadership team give careful consideration to what should come next for the company. With the appointment of Brian, we are putting in place the right next CEO who possesses the experience in rare and genetically defined diseases, including hematology, to drive our strategy forward and deepen our ability to deliver for patients and shareholders.”
Fouse will remain as chair of the board at Agios
“[E]ffective August 8, 2022, Jackie Fouse, Ph.D., will transition to the role of chair of the board of directors and Brian Goff will assume the role of chief executive officer,” Agios said.
Agios said: “Jacqualyn A. Fouse, Ph.D. will resign from the position of Chief Executive Officer and will assume the role of Chair of the Board of Directors (the “Board”), effective August 8, 2022 (the “Effective Date”).”
Share price decline since February 2019
The announcement follows a decline in Agios Pharmaceuticals Inc.’s share price of 56% since February 2019. February 2019 is the month in which Fouse’s tenure as CEO began.
In the position of CEO since 2019
Jackie Fouse became CEO of the Company in 2019.
Jacqualyn A. Fouse, Ph.D. joined Agios as chief executive officer on February 1, 2019 and has served as a member of the Company’s board of directors since December 2017.
Fouse served as executive chair of Dermavant Sciences, a biopharmaceutical company, from July 2017 until September 2018.
From September 2010 until June 2017, Fouse served in various capacities at Celgene Corporation, a biopharmaceutical company, or Celgene, serving as strategic advisor to the management executive committee from April 2017 to June 2017, president and chief operating officer from March 2016 to March 2017, president, hematology and oncology from August 2014 to February 2016, executive vice president and chief financial officer from February 2012 to July 2014, and senior vice president and chief financial officer from September 2010 to February 2012.
Prior to joining Celgene, Fouse served as chief financial officer of Bunge Limited, or Bunge, a global agribusiness and food company, from 2007 to 2010.
Prior to joining Bunge, Fouse served as senior vice president, chief financial officer and corporate strategy at Alcon Laboratories, Inc., or Alcon, a global medical company, from 2006 to 2007, and as its senior vice president and chief financial officer from 2002 to 2006.
Prior to her time with Alcon she held a variety of senior leadership roles with international companies.
Fouse is also a director and member of the audit committee and nominating and corporate governance committee of Incyte Corporation, or Incyte, a publicly traded biopharmaceutical company, and was a director of Perrigo Company, a publicly traded pharmaceutical manufacturer, Celgene and Dick’s Sporting Goods, Inc., a publicly traded sporting goods retailer.
Fouse earned a B.A. and an M.A. in Economics and a Ph.D. in Finance from the University of Texas at Arlington.
She also earned a Masters in Environmental Management from the Yale University School of Forestry and Environmental Studies.
Push-out Score determined
The Push-out Score™ determined by exechange gauges the pressure surrounding Jackie Fouse’s move on a scale of 0 to 10.
exechange reached out to Agios and offered the company the opportunity to comment on the score.
Read the full story in the exechange report 29.2022 ($).